ImmunoPET Targeting Receptor Tyrosine Kinase: Clinical Applications

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Dec 23

PMID 38136430

Authors

Flavia Linguanti

Elisabetta Maria Abenavoli

Raffaella Calabretta

Valentina Berti

Egesta Lopci

Affiliations

Soon will be listed here.

Abstract

Receptor tyrosine kinases, or RTKs, are one large family of cell surface receptors involved in signal transduction, which represent an integral part of the signaling pathways. They play a crucial role in most important cellular processes, starting with the cell cycle, proliferation and differentiation, as well as cell migration, metabolism and survival. The introduction of ImmunoPET evaluating the expression of RTKs by specific monoclonal antibodies (mAbs) or antibody fragments is regarded as a promising tool for imaging treatment efficacy and developing anticancer therapeutics. Our review focuses mainly on the current clinical research regarding ImmunoPET targeting RTKs, with particular interest in the epidermal growth factor family, or HER family, and vascular endothelial-derived growth factor/receptor.

References

Hynes N, MacDonald G . ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009; 21(2):177-84. DOI: 10.1016/j.ceb.2008.12.010. View

Voldborg B, Damstrup L, Spang-Thomsen M, Poulsen H . Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol. 1998; 8(12):1197-206. DOI: 10.1023/a:1008209720526. View

Benedetto R, Massicano A, Crenshaw B, Oliveira R, Reis R, Araujo E . Zr-DFO-Cetuximab as a Molecular Imaging Agent to Identify Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma. Cancer Biother Radiopharm. 2019; 34(5):288-296. PMC: 6588098. DOI: 10.1089/cbr.2018.2616. View

Wang Y, Fei D, Vanderlaan M, Song A . Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2005; 7(4):335-45. DOI: 10.1007/s10456-004-8272-2. View

Bensch F, Brouwers A, Lub-de Hooge M, de Jong J, van der Vegt B, Sleijfer S . Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up. Eur J Nucl Med Mol Imaging. 2018; 45(13):2300-2306. PMC: 6208812. DOI: 10.1007/s00259-018-4099-8. View

Gan H, Millward M, Jalving M, Garrido-Laguna I, Lickliter J, Schellens J . A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors. Oncologist. 2021; 26(10):e1844-e1853. PMC: 8488777. DOI: 10.1002/onco.13860. View

Mishra R, Patel H, Alanazi S, Yuan L, Garrett J . HER3 signaling and targeted therapy in cancer. Oncol Rev. 2018; 12(1):355. PMC: 6047885. DOI: 10.4081/oncol.2018.355. View

Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C . Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma. J Nucl Med. 2015; 57(1):27-33. DOI: 10.2967/jnumed.115.162024. View

Hoang T, Mandleywala K, Viray T, Tan K, Lewis J, Pereira P . EGFR-Targeted ImmunoPET of UMUC3 Orthotopic Bladder Tumors. Mol Imaging Biol. 2022; 24(4):511-518. PMC: 10187976. DOI: 10.1007/s11307-022-01708-2. View

10.

Divgi C, Welt S, KRIS M, Real F, Yeh S, Gralla R . Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst. 1991; 83(2):97-104. DOI: 10.1093/jnci/83.2.97. View

11.

van Scheltinga A, Lub-de Hooge M, Abiraj K, Schroder C, Pot L, Bossenmaier B . ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116. MAbs. 2014; 6(4):1051-8. PMC: 4171008. DOI: 10.4161/mabs.29097. View

12.

Blick S, Scott L . Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs. 2007; 67(17):2585-607. DOI: 10.2165/00003495-200767170-00008. View

13.

Gaykema S, Brouwers A, Lub-de Hooge M, Pleijhuis R, Timmer-Bosscha H, Pot L . 89Zr-bevacizumab PET imaging in primary breast cancer. J Nucl Med. 2013; 54(7):1014-8. DOI: 10.2967/jnumed.112.117218. View

14.

Li Q, Yuan Z, Cao B . The function of human epidermal growth factor receptor-3 and its role in tumors (Review). Oncol Rep. 2013; 30(6):2563-70. DOI: 10.3892/or.2013.2754. View

15.

Amin D, Campbell M, Moasser M . The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol. 2010; 21(9):944-50. PMC: 2991618. DOI: 10.1016/j.semcdb.2010.08.007. View

16.

Oosting S, Brouwers A, van Es S, Nagengast W, Oude Munnink T, Lub-de Hooge M . 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. J Nucl Med. 2014; 56(1):63-9. DOI: 10.2967/jnumed.114.144840. View

17.

Esparis-Ogando A, Carlos Montero J, Arribas J, Ocana A, Pandiella A . Targeting the EGF/HER Ligand-Receptor System in Cancer. Curr Pharm Des. 2016; 22(39):5887-5898. DOI: 10.2174/1381612822666160715132233. View

18.

Chua Y, Cunningham D . Panitumumab. Drugs Today (Barc). 2006; 42(11):711-9. DOI: 10.1358/dot.2006.42.11.1032061. View

19.

van Dongen G, Poot A, Vugts D . PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. Tumour Biol. 2012; 33(3):607-15. PMC: 3342498. DOI: 10.1007/s13277-012-0316-4. View

20.

Even A, Hamming-Vrieze O, van Elmpt W, Winnepenninckx V, Heukelom J, Tesselaar M . Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach. Oncotarget. 2016; 8(3):3870-3880. PMC: 5354801. DOI: 10.18632/oncotarget.13910. View